A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
The ISOLDE COOLer (ISCOOL) is located downstream from the HRS, and extends up to the merging switchyard joining the two mass separator beams. ISCOOL is a general-purpose Radio Frequency Quadrupole Cooler and Buncher (RFQCB), with the purpose of cooling (improving the beam quality) and bunching the RIB from the HRS. Incoming ions collide with the neutral buffer gas, losing their energy, and then are radially confined. The beam is then extracted from ISCOOL.
Artificially acquired active immunity can be induced by a vaccine, a substance that contains antigen. A vaccine stimulates a primary response against the antigen without causing symptoms of the disease. The term vaccination was coined by Richard Dunning, a colleague of Edward Jenner, and adapted by Louis Pasteur for his pioneering work in vaccination. The method Pasteur used entailed treating the infectious agents for those diseases, so they lost the ability to cause serious disease. Pasteur adopted the name vaccine as a generic term in honor of Jenner's discovery, which Pasteur's work built upon. In 1807, Bavaria became the first group to require their military recruits to be vaccinated against smallpox, as the spread of smallpox was linked to combat. Subsequently, the practice of vaccination would increase with the spread of war. There are four types of traditional vaccines:
The light chain gene has three gene segments. These include: the light chain variable region (V), joining region (J), and constant region (C) gene segments. The variable region of light is therefore encoded by the rearrangement of VJ segments. The light chain can be either kappa,κ or lambda,λ. This process takes place at the level of mRNAs processing. Random rearrangements and recombinations of the gene segments at DNA level to form one kappa or lambda light chain occurs in an orderly fashion. As a result, "a functional variable region gene of a light chain contains two coding segments that are separated by a non-coding DNA sequence in unrearranged germ-line DNA".
Sources: en.wikipedia.org
=== Government of Qatar === The Qatari government denied any involvement in the scandal with the Qatari Mission to the European Union saying, "[t]he State of Qatar categorically rejects any attempts to associate it with accusations of misconduct. Any association of the Qatari government with the reported claims is baseless and gravely misinformed. The State of Qatar works through institution-to-institution engagement and operates in full compliance with international laws and regulations." They later accused the United Arab Emirates of "orchestrating" the scandal. Journalist Jack Parrock reported that the Qatari government claimed "everyone" believed that the UAE was behind it. According to the Qatari state-funded Middle East Monitor "[t]he European Union Parliament has opened an official investigation into corruption cases and suspicions involving senior officials from the UAE to launch a smear campaign against Qatar coinciding with hosting the 2022 FIFA World Cup." Qatar claims that "since 2017, Qatar feels it has been the victim of a media attack orchestrated by Abu Dhabi, with false documents and fake news." The Qatari government stated that they were being "exclusively criticised and attacked" by Belgian authorities and conveyed disappointment that the Belgian government "made no effort to engage with our government to establish the facts". Qatar warned that the continued implication of Qatar in the scandal will "negatively effect" the energy cooperation between the EU and Qatar.
=== Structure === The carotid sheath is a fibrous connective tissue formation surrounding several important structures of the neck. It is thicker around the arteries than around the vein, allowing the vein to expand. The three major fascial layers in the neck contribute to the carotid sheath: the investing fascia, the pretracheal fascia, and the prevertebral fascia. The carotid sheath has limited loose connective tissue.
==== Metal exchange ==== Post-synthetic modification techniques can also be used to exchange an existing metal ion in a prefabricated MOF with a new metal ion by metal ion exchange. The complete metal metathesis from an integral part of the framework has been achieved without altering the framework or pore structure of the MOF. Similarly to post-synthetic ligand exchange, post-synthetic metal exchange is performed by washing prefabricated MOF crystals with solvent and then soaking the crystal in a solution of the new metal. Post-synthetic metal exchange allows for a simple route to the formation of MOFs with the same framework yet different metal ions.
=== Grand Lodge of Colon vs. Provincial Mother Lodge of Havana === By 1870, only seven lodges were left in the entire island of Cuba. On May 26, 1870, the former GOCA Lodges around Havana, distancing themselves from the Colon Freemasonry of Santiago de Cuba, established the First Provincial Mother Lodge of Havana. They elected as Grand Master Severino Fernández Mora, who was a former Spanish Army physician in the Military Health Service of Spain that had been exiled from the country for revolutionary activities and ideas. Quickly, the Supreme Council recalled the warrant for the Mother Lodge. On April 11, 1873, the Grand Lodge of Colon resumed its work, despite the fear of reprisal. In 1875, they arranged with the Supreme Council to secure jurisdiction over Symbolic Masonry and the authority to charter new lodges. In 1873, the Supreme Council sent out a decree that all bodies in Cuba were to be directed by the Consistory. This included the Grand Lodge of Colon. The Supreme Council also decreed that members of the 31st through 33rd Degrees were granted honorary membership at any Lodge in Cuba. On May 23, 1875, the Second Provincial Mother Lodge of Havana was established. In 1875, the Supreme Council sent two delegates to the Congress of Supreme Councils in Lausanne, Switzerland. Freemasons in Cuba were surprised that they were accepted where Spain's delegation was refused attendance. The Cuban representatives, David Elías Pierre and Benjamín Odio, became signatories to the Pact of Confederation of the Supreme Councils which the Congress produced.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.